Myoblast models of skeletal muscle hypertrophy and atrophy

Current Opinion in Clinical Nutrition and Metabolic Care

Volumn 14, Issue 3, 2011, Pages 230-236

  Sharples, Adam P ^a,b   Stewart, Claire E ^b  

^a UNIVERSITY OF BEDFORDSHIRE   (United Kingdom)

^b MANCHESTER METROPOLITAN UNIVERSITY   (United Kingdom)

Author keywords

insulin like growth factor I; muscle precursor cell; myostatin; satellite cell; three dimensional muscle constructs

Indexed keywords

MAMMALIAN TARGET OF RAPAMYCIN; MICRORNA; MYOSTATIN; PROTEIN KINASE B; SOMATOMEDIN C;

ARTICLE; CELL CULTURE; EXPERIMENTAL MODEL; HUMAN; MECHANICAL STIMULATION; MECHANOTRANSDUCTION; MUSCLE ATROPHY; MUSCLE HYPERTROPHY; MYOBLAST; NONHUMAN; PREMATURE AGING; PROTEIN DEGRADATION; PROTEIN SYNTHESIS; SKELETAL MUSCLE;

HUMANS; HYPERTROPHY; INSULIN-LIKE GROWTH FACTOR I; MODELS, BIOLOGICAL; MUSCLE, SKELETAL; MUSCULAR ATROPHY; MYOBLASTS, SKELETAL; MYOSTATIN; PROTEIN BIOSYNTHESIS; SIGNAL TRANSDUCTION; STRESS, MECHANICAL;

EID: 79955010071     PISSN: 13631950     EISSN: 14736519     Source Type: Journal    
DOI: 10.1097/MCO.0b013e3283457ade     Document Type: Article

References (58)

1. Amthor H, Otto A, Vulin A, et al. Muscle hypertrophy driven by myostatin blockade does not require stem/precursor-cell activity. Proc Natl Acad Sci USA 2009; 106:7479-7484.
2. Schultz SS, Lucas PA. Human stem cells isolated from adult skeletal muscle differentiate into neural phenotypes. J Neurosci Methods 2006; 152:144-155. (Pubitemid 43343485)
3. Lee KS, Kim HJ, Li QL, et al. Runx2 is a common target of transforming growth factor beta1 and bone morphogenetic protein 2, and cooperation between Runx2 and Smad5 induces osteoblast-specific gene expression in the pluripotent mesenchymal precursor cell line C2C12. Mol Cell Biol 2000; 20:8783-8792.
4. Katagiri T, Yamaguchi A, Komaki M, et al. Bone morphogenetic protein-2 converts the differentiation pathway of C2C12 myoblasts into the osteoblast lineage. J Cell Biol 1994; 127:1755-1766. (Pubitemid 24380911)
5. Peng H, Huard J. Muscle-derived stem cells for musculoskeletal tissue regeneration and repair. Transpl Immunol 2004; 12:311-319. (Pubitemid 38639726)
6. Lee SJ, Lee EJ, Kim SH, et al. IL-17A promotes transdifferentiation of mouse myoblast cells (C2C12) into adipocytes by increasing the expression of peroxisome proliferator-activated receptor gamma through CAAT/enhancer binding protein beta signaling. Biotechnol Lett 2011; 33:229-235.
7. Saini A, Faulkner S, Al-Shanti N, Stewart C. Powerful signals for weak muscles. Ageing Res Rev 2009; 8:251-267.
8. Mudera V, Smith AS, Brady M, Lewis MP. The effect of cell density on the maturation and contractile ability of muscle derived cells in a 3D tissueengineered skeletal muscle model and determination of the cellular and mechanical stimuli required for the synthesis of a postural phenotype. J Cell Physiol 2010; 225:646-653.
9. Dennis RG, Kosnik PE 2nd. Excitability and isometric contractile properties of mammalian skeletal muscle constructs engineered in vitro. In Vitro Cell Dev Biol Anim 2000; 36:327-335. (Pubitemid 30619599)
10. Scime A, Rudnicki MA. Anabolic potential and regulation of the skeletal muscle satellite cell populations. Curr Opin Clin Nutr Metab Care 2006; 9:214-219. (Pubitemid 44097831)
11. Stewart CE, Rotwein P. Growth, differentiation, and survival: multiple physiological functions for insulin-like growth factors. Physiol Rev 1996; 76:1005-1026. (Pubitemid 26346814)
12. Jacquemin V, Furling D, Bigot A, et al. IGF-1 induces human myotube hypertrophy by increasing cell recruitment. Exp Cell Res 2004; 299:148-158. (Pubitemid 39078390)
13. Quinn LS, Anderson BG, Plymate SR. Muscle-specific overexpression of the type 1 IGF receptor results in myoblast-independent muscle hypertrophy via PI3K, and not calcineurin, signaling. Am J Physiol Endocrinol Metab 2007; 293:E1538-E1551. (Pubitemid 350255103)
14. Matheny RW, Merritt E, Zannikos SV, et al. Serum IGF-I-deficiency does not prevent compensatory skeletal muscle hypertrophy in resistance exercise. Exp Biol Med (Maywood) 2009; 234:164-170.
15. Stewart CE, Pell JM. Point:Counterpoint: IGF is/is not the major physiological regulator of muscle mass. Point: IGF is the major physiological regulator of muscle mass. J Appl Physiol 2010; 108:1820-1824.
16. Flueck M, Goldspink G. Point:Counterpoint: IGF is/is not the major physiological regulator of muscle mass. Counterpoint: IGF is not the major physiological regulator of muscle mass. J Appl Physiol 2010; 108:1821-1823; discussion 3-4; author reply 33.
17. Sharples AP, Al-Shanti N, Stewart CE. C2 and C2C12 murine skeletal myoblast models of atrophic and hypertrophic potential: relevance to disease and ageing? J Cell Physiol 2010; 225:240-250.
18. Stewart CE, Rotwein P. Insulin-like growth factor-II is an autocrine survival factor for differentiating myoblasts. J Biol Chem 1996; 271:11330-11338. (Pubitemid 26155970)
19. Foulstone EJ, Huser C, Crown AL, et al. Differential signalling mechanisms predisposing primary human skeletal muscle cells to altered proliferation and differentiation: roles of IGF-I and TNFalpha. Exp Cell Res 2004; 294:223-235. (Pubitemid 38229793)
20. Florini JR, Ewton DZ, Coolican SA. Growth hormone and the insulin-like growth factor system in myogenesis. Endocr Rev 1996; 17:481-517. (Pubitemid 26346639)
21. Sasai N, Agata N, Inoue-Miyazu M, et al. Involvement of PI3K/Akt/TOR pathway in stretch-induced hypertrophy of myotubes. Muscle Nerve 2010; 41:100-106.
22. Hornberger TA, Chu WK, Mak YW, et al. The role of phospholipase D and phosphatidic acid in the mechanical activation of mTOR signaling in skeletal muscle. Proc Natl Acad Sci USA 2006; 103:4741-4746.
23. O'Neil TK, Duffy LR, Frey JW, Hornberger TA. The role of phosphoinositide 3-kinase and phosphatidic acid in the regulation of mammalian target of rapamycin following eccentric contractions. J Physiol 2009; 587:3691-3701.
24. Sun Y, Bilan PJ, Liu Z, Klip A. Rab8A and Rab13 are activated by insulin and regulate GLUT4 translocation in muscle cells. Proc Natl Acad Sci USA 2010; 107:19909-19914.
25. Anthony JC, Yoshizawa F, Anthony TG, et al. Leucine stimulates translation initiation in skeletal muscle of postabsorptive rats via a rapamycin-sensitive pathway. J Nutr 2000; 130:2413-2419.
26. Anthony JC, Anthony TG, Kimball SR, et al. Orally administered leucine stimulates protein synthesis in skeletal muscle of postabsorptive rats in association with increased eIF4F formation. J Nutr 2000; 130:139-145. (Pubitemid 30073785)
27. Findlay GM, Yan L, Procter J, et al. A MAP4 kinase related to Ste20 is a nutrient-sensitive regulator of mTOR signalling. Biochem J 2007; 403:13-20. (Pubitemid 46569862)
28. DeYoung MP, Horak P, Sofer A, et al. Hypoxia regulates TSC1/2-mTOR signaling and tumor suppression through REDD1-mediated 14-3-3 shuttling. Genes Dev 2008; 22:239-251.
29. Drummond MJ, Miyazaki M, Dreyer HC, et al. Expression of growth-related genes in young and older human skeletal muscle following an acute stimulation of protein synthesis. J Appl Physiol 2009; 106:1403-1411.
30. Spangenburg EE, Le Roith D, Ward CW, Bodine SC. A functional insulin-like growth factor receptor is not necessary for load-induced skeletal muscle hypertrophy. J Physiol 2008; 586:283-291.
31. Heron-Milhavet L, Mamaeva D, LeRoith D, et al. Impaired muscle regeneration and myoblast differentiation in mice with a muscle-specific KO of IGF-IR. J Cell Physiol 2010; 225:1-6.
32. Tatsumi R. Mechano-biology of skeletal muscle hypertrophy and regeneration: possible mechanism of stretch-induced activation of resident myogenic stem cells. Anim Sci J 2010; 81:11-20.
33. Yamada M, Tatsumi R, Yamanouchi K, et al. High concentrations of HGF inhibit skeletal muscle satellite cell proliferation in vitro by inducing expression of myostatin: a possible mechanism for reestablishing satellite cell quiescence in vivo. Am J Physiol Cell Physiol 2010; 298:C465-C476.
34. Morgan J, Rouche A, Bausero P, et al. MMP-9 overexpression improves myogenic cell migration and engraftment. Muscle Nerve 2010; 42:584-595.
35. Armstrong DD, Esser KA. Wnt/beta-catenin signaling activates growth-control genes during overload-induced skeletal muscle hypertrophy. Am J Physiol Cell Physiol 2005; 289:C853-C859. (Pubitemid 41361641)
36. Gentile MA, Nantermet PV, Vogel RL, et al. Androgen-mediated improvement of body composition and muscle function involves a novel early transcriptional program including IGF1, mechano growth factor, and induction of {beta}-catenin. J Mol Endocrinol 2010; 44:55-73.
37. Chen JF, Mandel EM, Thomson JM, et al. The role of microRNA-1 and microRNA-133 in skeletal muscle proliferation and differentiation. Nature genetics 2006; 38:228-233. (Pubitemid 43177239)
38. McCarthy JJ, Esser KA. Anabolic and catabolic pathways regulating skeletal muscle mass. Curr Opin Clin Nutr Metab Care 2010; 13:230-235.
39. Glass D, Roubenoff R. Recent advances in the biology and therapy of muscle wasting. Ann N Y Acad Sci 2010; 1211:25-36.
40. McPherron AC, Lawler AM, Lee SJ. Regulation of skeletal muscle mass in mice by a new TGF-beta superfamily member. Nature 1997; 387:83-90. (Pubitemid 27202654)
41. McPherron AC, Lee SJ. Double muscling in cattle due to mutations in the myostatin gene. Proc Natl Acad Sci USA 1997; 94:12457-12461. (Pubitemid 27492550)
42. Lee SJ. Sprinting without myostatin: a genetic determinant of athletic prowess. Trends Genet 2007; 23:475-477.
43. Wagner KR, Fleckenstein JL, Amato AA, et al. A phase I/II trial of MYO-029 in adult subjects with muscular dystrophy. Ann Neurol 2008; 63:561-571.
44. Castro-Gago M, Blanco-Barca MO, Eiris-Punal J, et al. Myostatin expression in muscular dystrophies and mitochondrial encephalomyopathies. Pediatr Neurol 2006; 34:281-284.
45. Rios R, Fernandez-Nocelos S, Carneiro I, et al. Differential response to exogenous and endogenous myostatin in myoblasts suggests that myostatin acts as an autocrine factor in vivo. Endocrinology 2004; 145:2795-2803. (Pubitemid 38686229)
46. Langen RC, Van Der Velden JL, Schols AM, et al. Tumor necrosis factor-alpha inhibits myogenic differentiation through MyoD protein destabilization. FASEB J 2004; 18:227-237. (Pubitemid 38186242)
47. McFarlane C, Plummer E, Thomas M, et al. Myostatin induces cachexia by activating the ubiquitin proteolytic system through an NF-kappaB-independent, FoxO1-dependent mechanism. J Cell Physiol 2006; 209:501-514. (Pubitemid 44484641)
48. Trendelenburg AU, Meyer A, Rohner D, et al. Myostatin reduces Akt/TORC1/p70S6K signaling, inhibiting myoblast differentiation and myotube size. Am J Physiol Cell Physiol 2009; 296:C1258-C1270.
49. Tsuchida K, Nakatani M, Uezumi A, et al. Signal transduction pathway through activin receptors as a therapeutic target of musculoskeletal diseases and cancer. Endocr J 2008; 55:11-21. (Pubitemid 351520175)
50. Rebbapragada A, Benchabane H, Wrana JL, et al. Myostatin signals through a transforming growth factor beta-like signaling pathway to block adipogenesis. Mol Cell Biol 2003; 23:7230-7242. (Pubitemid 37211004)
51. Sartori R, Milan G, Patron M, et al. Smad2 and 3 transcription factors control muscle mass in adulthood. Am J Physiol Cell Physiol 2009; 296:C1248-C1257.
52. Welle SL. Myostatin and muscle fiber size. Focus on 'Smad2 and 3 transcription factors control muscle mass in adulthood' and 'Myostatin reduces Akt/TORC1/p70S6K signaling, inhibiting myoblast differentiation and myotube size'. Am J Physiol Cell Physiol 2009; 296:C1245-C1247.
53. Cong H, Sun LQ, Liu C, Tien P. Inhibition of atrogin-1/MAFbx expression by adenovirus-delivered shRNAs attenuates muscle atrophy in fasting mice. Hum Gene Ther 2011 [Epub ahead of print].
54. Whittemore LA, Song K, Li X, et al. Inhibition of myostatin in adult mice increases skeletal muscle mass and strength. Biochem Biophys Res Commun 2003; 300:965-971. (Pubitemid 36262030)
55. Lee SJ, Reed LA, Davies MV, et al. Regulation of muscle growth by multiple ligands signaling through activin type II receptors. Proc Natl Acad Sci USA 2005; 102:18117-18122. (Pubitemid 41798511)
56. McFarlane C, Hennebry A, Thomas M, et al. Myostatin signals through Pax7 to regulate satellite cell self-renewal. Exp Cell Res 2008; 314:317-329. (Pubitemid 350225602)
57. Leger B, Derave W, De Bock K, et al. Human sarcopenia reveals an increase in SOCS-3 and myostatin and a reduced efficiency of Akt phosphorylation. Rejuvenation research 2008; 11:163-175. (Pubitemid 351271633)
58. Amthor H, Macharia R, Navarrete R, et al. Lack of myostatin results in excessive muscle growth but impaired force generation. Proc Natl Acad Sci USA 2007; 104:1835-1840. (Pubitemid 46239865)